A report reveals that the majority of weight loss drug users in Finland are likely working and relatively affluent, with significant financial implications for the usage of these medications.
A recent report from KELA, Finland's Social Insurance Institution, indicates that there is limited data regarding the demographic backgrounds of users of weight loss medications. Specialist researcher Terhi Kurko noted that statistically, most of these users are presumably employed and enjoy relatively high incomes. This assumption is based on the fact that privately purchased weight loss drugs represent a considerable expense for individuals. In addition to telling about the demographics, the report highlighted that over 50% of users are aged between 45 and 65 years, with women making up approximately 70% of the users compared to 30% who are men.
Furthermore, the report presents a staggering estimate that a weight loss medication approved by the EU's drug authority could cost around 3,000 euros annually. Kurko expressed concerns regarding the affordability of such medications, stating that this expense is significant and may not be financially viable for everyone. This raises broader questions about access to effective health treatments and the socioeconomic factors that determine who can utilize them.
In Finland, obesity is being managed with medications traditionally used for diabetes, indicating a shift in treatment paradigms. One of the branded names for a weight loss drug is Wegovy, while another drug, Ozempic, has gained popularity as a weight loss agent. These trends suggest a growing reliance on pharmaceuticals for weight management, highlighting the need for further research on the implications of such treatments in the health landscape of Finland and beyond.
